Skip to content
value.today

Hologic, Inc.: peers

Change the peers

Hologic, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Hologic, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Hologic, Inc., Glaukos Corporation, Baxter International Inc., Repligen Corporation, The Cooper Companies, Inc., West Pharmaceutical Services, Inc., ResMed Inc., Merit Medical Systems, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureHologic, Inc.base
HOLX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Glaukos Corporation
GKOS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Baxter International Inc.
BAX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Repligen Corporation
RGEN · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
The Cooper Companies, Inc.
COO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
West Pharmaceutical Services, Inc.
WST · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
ResMed Inc.
RMD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Merit Medical Systems, Inc.
MMSI · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$16.9 Blast known, Mar 8, 2026 · Market dataLast known value: no current one3rd of 8$14.4 BOct 30, 2026 · Market data4th of 8$12.9 BOct 28, 2026 · Market data5th of 8$11.5 BOct 27, 2026 · Market data6th of 8$11.3 BOct 29, 2026 · Market data7th of 8$27.1 BOct 21, 2026 · Market data2nd of 8$35.3 BOct 28, 2026 · Market data1st of 8$5.6 BOct 26, 2026 · Market data8th of 8$13.6 B8 ranked
Revenue (Better neither way: ranked highest first)$4.1 BFY2025 · SEC3rd of 8$507 MFY2025 · SEC8th of 8$11.2 BFY2025 · SEC1st of 8$738 MFY2025 · SEC7th of 8$4.1 BFY2025 · SEC4th of 8$3.1 BFY2025 · SEC5th of 8$5.7 BFY2026 · SEC2nd of 8$1.5 BFY2025 · SEC6th of 8$3.6 B8 ranked
Net income (Higher is better)$566 MFY2025 · SEC2nd of 8$-188 MFY2025 · SEC7th of 8$-957 MFY2025 · SEC8th of 8$49 MFY2025 · SEC6th of 8$375 MFY2025 · SEC4th of 8$494 MFY2025 · SEC3rd of 8$1.5 BFY2026 · SEC1st of 8$128 MFY2025 · SEC5th of 8$252 M8 ranked
Employees (Better neither way: ranked highest first)6,944As on 2022 · Profile4th of 81,094December 31, 2025 · Profile7th of 837,500December 31, 2025 · Profile1st of 82,000December 31, 2025 · Profile6th of 8500October 31, 2025 · Profile8th of 810,800December 31, 2025 · Profile3rd of 811,370June 30, 2026 · Profile2nd of 86,446As on 2021 · Profile5th of 86,6958 ranked
Growth
Market cap change, 30 days (Higher is better)——————————————+6.6%30 days to Oct 26, 2026 · Market dataonly one with it+6.6%—
Revenue growth (Higher is better)+1.7%FY2025 · SEC8th of 830th34th+32.3%FY2025 · SEC1st of 878th87th+5.7%FY2025 · SEC6th of 839th48th+16.4%FY2025 · SEC2nd of 862nd73rd+5.1%FY2025 · SEC7th of 837th46th+6.3%FY2025 · SEC5th of 841st49th+9.8%FY2026 · SEC4th of 849th61st+11.8%FY2025 · SEC3rd of 854th65th+8.1%8 ranked
Revenue growth, 3 years a year (Higher is better)-5.5%FY2025 · SEC8th of 816th17th+21.5%FY2025 · SEC1st of 874th86th+3.8%FY2025 · SEC5th of 838th48th-2.7%FY2025 · SEC7th of 820th24th+7.3%FY2025 · SEC4th of 847th61st+2.1%FY2025 · SEC6th of 833rd41st+10.2%FY2026 · SEC2nd of 854th70th+9.6%FY2025 · SEC3rd of 852nd68th+5.6%8 ranked
Earnings per share growth (Higher is better)-25.0%FY2025 · SEC5th of 519th19th————————————-4.6%FY2025 · SEC4th of 531st33rd+1.5%FY2025 · SEC3rd of 540th40th+9.7%FY2026 · SEC1st of 551st50th+4.9%FY2025 · SEC2nd of 544th44th+1.5%5 ranked
Margins and returns
Gross margin (Higher is better)51.6%FY2025 · SEC5th of 838th65th55.7%FY2025 · SEC3rd of 845th69th30.1%FY2025 · SEC8th of 816th35th52.3%FY2025 · SEC4th of 839th66th65.5%FY2025 · SEC1st of 861st79th35.9%FY2025 · SEC7th of 822nd44th61.1%FY2026 · SEC2nd of 854th75th48.7%FY2025 · SEC6th of 834th62nd52.0%8 ranked
Operating margin (Higher is better)17.4%FY2025 · SEC3rd of 885th82nd-39.3%FY2025 · SEC8th of 834th17th-2.7%FY2025 · SEC7th of 854th35th7.5%FY2025 · SEC6th of 868th62nd16.7%FY2025 · SEC4th of 884th81st19.0%FY2025 · SEC2nd of 887th84th33.4%FY2026 · SEC1st of 896th95th12.2%FY2025 · SEC5th of 876th73rd14.4%8 ranked
Net margin (Higher is better)13.8%FY2025 · SEC3rd of 884th82nd-37.0%FY2025 · SEC8th of 835th17th-8.5%FY2025 · SEC7th of 849th28th6.6%FY2025 · SEC6th of 873rd66th9.2%FY2025 · SEC4th of 878th73rd16.1%FY2025 · SEC2nd of 886th85th26.9%FY2026 · SEC1st of 893rd93rd8.5%FY2025 · SEC5th of 876th71st8.8%8 ranked
Free cash flow margin (Higher is better)24.4%FY2025 · SEC2nd of 893rd92nd-4.4%FY2025 · SEC8th of 845th26th3.0%FY2025 · SEC7th of 858th45th12.7%FY2025 · SEC5th of 877th76th10.6%FY2025 · SEC6th of 873rd71st15.3%FY2025 · SEC3rd of 881st81st29.2%FY2026 · SEC1st of 896th95th14.2%FY2025 · SEC4th of 880th79th13.5%8 ranked
Return on equity (Higher is better)11.1%FY2025 · SEC3rd of 883rd68th-26.4%FY2025 · SEC8th of 856th25th-14.6%FY2025 · SEC7th of 863rd30th2.4%FY2025 · SEC6th of 874th46th4.6%FY2025 · SEC5th of 876th50th16.9%FY2025 · SEC2nd of 889th81st24.3%FY2026 · SEC1st of 893rd88th8.7%FY2025 · SEC4th of 879th60th6.6%8 ranked
Return on invested capital (Higher is better)10.7%FY2025 · SEC3rd of 648th50th————————2.3%FY2025 · SEC6th of 610th5th4.3%FY2025 · SEC5th of 616th13th18.7%FY2025 · SEC2nd of 677th76th27.4%FY2026 · SEC1st of 686th86th7.7%FY2025 · SEC4th of 628th32nd9.2%6 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————————————————19.8×price Oct 29, 2026 · Market data4th of 432nd52nd42.4×price Oct 21, 2026 · Market data1st of 466th83rd22.1×price Oct 28, 2026 · Market data3rd of 436th58th34.9×price Oct 26, 2026 · Market data2nd of 454th78th28.5×4 ranked
Price to sales (Better neither way: ranked highest first)————20.8×price Oct 30, 2026 · Market data1st of 784th94th1.1×price Oct 28, 2026 · Market data7th of 719th32nd14.3×price Oct 27, 2026 · Market data2nd of 779th92nd2.7×price Oct 29, 2026 · Market data6th of 740th56th8.0×price Oct 21, 2026 · Market data3rd of 769th86th6.2×price Oct 28, 2026 · Market data4th of 761st81st3.5×price Oct 26, 2026 · Market data5th of 748th66th6.2×7 ranked
Price to book (Better neither way: ranked highest first)————21.9×price Oct 30, 2026 · Market data1st of 793rd96th2.1×price Oct 28, 2026 · Market data6th of 739th49th5.5×price Oct 27, 2026 · Market data3rd of 770th78th1.4×price Oct 29, 2026 · Market data7th of 726th33rd8.5×price Oct 21, 2026 · Market data2nd of 781st87th5.4×price Oct 28, 2026 · Market data4th of 769th77th3.5×price Oct 26, 2026 · Market data5th of 756th67th5.4×7 ranked
Free cash flow yield (Higher is better)————-0.2%price Oct 30, 2026 · Market data7th of 768th37th2.6%price Oct 28, 2026 · Market data4th of 778th50th0.8%price Oct 27, 2026 · Market data6th of 772nd40th3.8%price Oct 29, 2026 · Market data3rd of 782nd59th1.7%price Oct 21, 2026 · Market data5th of 775th45th4.7%price Oct 28, 2026 · Market data1st of 786th65th3.9%price Oct 26, 2026 · Market data2nd of 782nd59th2.6%7 ranked
Financial strength
Debt to equity (Lower is better)0.5×FY2025 · SEC6th of 753rd44th————1.5×FY2025 · SEC7th of 786th80th0.3×FY2025 · SEC3rd of 736th27th0.3×FY2025 · SEC4th of 739th30th0.1×FY2025 · SEC1st of 715th11th0.1×FY2026 · SEC1st of 715th11th0.5×FY2025 · SEC5th of 752nd41st0.3×7 ranked
Net debt to EBITDA (Lower is better)0.5×FY2025 · SEC4th of 733rd27th————11.1×FY2025 · SEC7th of 795th95th-0.2×FY2025 · SEC3rd of 723rd15th2.2×FY2025 · SEC6th of 755th52nd-0.8×FY2025 · SEC1st of 714th9th-0.5×FY2026 · SEC2nd of 717th11th0.9×FY2025 · SEC5th of 739th33rd0.5×7 ranked
Interest cover (Higher is better)————————-1.1×FY2025 · SEC3rd of 366th42nd2.4×FY2025 · SEC2nd of 381st62nd————38.7×FY2025 · SEC1st of 398th95th————————2.4×3 ranked
Piotroski F-score (Higher is better)6 of 9FY2025 · SEC5th of 7——4 of 9FY2025 · SEC7th of 77 of 9FY2025 · SEC1st of 76 of 9FY2025 · SEC5th of 77 of 9FY2025 · SEC1st of 77 of 9FY2026 · SEC1st of 77 of 9FY2025 · SEC1st of 77.0 of 97 ranked
Scorecard
Scorecard (Higher is better)11 of 18FY2025 · Scorecard5th of 86 of 20FY2025 · Scorecard8th of 810 of 28FY2025 · Scorecard7th of 811 of 26FY2025 · Scorecard6th of 820 of 27FY2025 · Scorecard2nd of 820 of 30FY2025 · Scorecard4th of 824 of 29FY2026 · Scorecard1st of 817 of 24FY2025 · Scorecard3rd of 864% passed8 ranked
Valuation checks (Higher is better)——0 of 5FY2025 · Scorecard5th of 72 of 6FY2025 · Scorecard2nd of 70 of 6FY2025 · Scorecard5th of 74 of 6FY2025 · Scorecard1st of 70 of 6FY2025 · Scorecard5th of 72 of 6FY2026 · Scorecard2nd of 71 of 6FY2025 · Scorecard4th of 717% passed7 ranked
Growth checks (Higher is better)1 of 6FY2025 · Scorecard8th of 84 of 6FY2025 · Scorecard4th of 82 of 6FY2025 · Scorecard7th of 83 of 6FY2025 · Scorecard6th of 85 of 6FY2025 · Scorecard3rd of 84 of 6FY2025 · Scorecard4th of 86 of 6FY2026 · Scorecard1st of 86 of 6FY2025 · Scorecard1st of 867% passed8 ranked
Profitability checks (Higher is better)4 of 6FY2025 · Scorecard3rd of 80 of 5FY2025 · Scorecard8th of 81 of 5FY2025 · Scorecard7th of 82 of 6FY2025 · Scorecard6th of 84 of 6FY2025 · Scorecard3rd of 85 of 6FY2025 · Scorecard2nd of 86 of 6FY2026 · Scorecard1st of 84 of 6FY2025 · Scorecard3rd of 867% passed8 ranked
Financial health checks (Higher is better)4 of 4FY2025 · Scorecard1st of 82 of 3FY2025 · Scorecard7th of 83 of 6FY2025 · Scorecard8th of 85 of 6FY2025 · Scorecard6th of 85 of 5FY2025 · Scorecard1st of 86 of 6FY2025 · Scorecard1st of 85 of 5FY2026 · Scorecard1st of 85 of 5FY2025 · Scorecard1st of 8100% passed8 ranked
Shareholder returns checks (Higher is better)2 of 2FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard8th of 82 of 5FY2025 · Scorecard7th of 81 of 2FY2025 · Scorecard5th of 82 of 4FY2025 · Scorecard5th of 85 of 6FY2025 · Scorecard3rd of 85 of 6FY2026 · Scorecard3rd of 81 of 1FY2025 · Scorecard1st of 867% passed8 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)96.3%2026-Q1 · 13F7th of 8100.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8100.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8110.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8103.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 899.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 865.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8104.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8100.4%8 ranked
Institutions holding (Better neither way: ranked highest first)6982026-Q1 · 13F4th of 84222026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 87382026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 85242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 86462026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 88782026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 88842026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 84242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 86728 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)+0.6 pp2026-Q1 against 2025-Q4 · 13F7th of 8+4.4 pp2026-Q2 against 2026-Q1 · 13F3rd of 8+5.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 8+1.1 pp2026-Q2 against 2026-Q1 · 13F6th of 8+2.8 pp2026-Q2 against 2026-Q1 · 13F4th of 8-0.4 pp2026-Q2 against 2026-Q1 · 13F8th of 8+2.4 pp2026-Q2 against 2026-Q1 · 13F5th of 8+5.3 pp2026-Q2 against 2026-Q1 · 13F1st of 8+2.6 pp8 ranked
Dividends
Dividend yield (Higher is better)————————2.7%FY2025 · SEC1st of 485th63rd————0.0%FY2025 · SEC4th of 46th2nd0.2%FY2025 · SEC3rd of 420th9th1.0%FY2026 · SEC2nd of 451st26th————0.6%4 ranked
Shareholder yield (Higher is better)————————2.7%FY2025 · SEC2nd of 557th44th0.0%FY2025 · SEC5th of 57th3rd2.6%FY2025 · SEC3rd of 554th42nd0.7%FY2025 · SEC4th of 527th18th3.0%FY2026 · SEC1st of 560th48th————2.6%5 ranked
Dividend payout (Better neither way: ranked highest first)————————————————0.0%FY2025 · SEC3rd of 32nd1st12.4%FY2025 · SEC2nd of 328th12th22.9%FY2026 · SEC1st of 341st26th————12.4%3 ranked
Dividend per share (Better neither way: ranked highest first)————$0.52FY2025 · SEC3rd of 3————$0.86FY2025 · SEC2nd of 3$2.40FY2026 · SEC1st of 3——$0.863 ranked
Years of dividend raises (Higher is better)————————————12to 2025 · SEConly one with it——12—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Hologic, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Glaukos Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Baxter International Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Repligen Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; The Cooper Companies, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; West Pharmaceutical Services, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; ResMed Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Merit Medical Systems, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Hologic, Inc.17.4%FY2025
85th percentile in Healthcaremedian -7.7%, 674 companies
82nd percentile in USAmedian 3.5%, 2,594 companies
Glaukos Corporation-39.3%FY2025
34th percentile in Healthcaremedian -7.7%, 674 companies
17th percentile in USAmedian 3.5%, 2,594 companies
Baxter International Inc.-2.7%FY2025
54th percentile in Healthcaremedian -7.7%, 674 companies
35th percentile in USAmedian 3.5%, 2,594 companies
Repligen Corporation7.5%FY2025
68th percentile in Healthcaremedian -7.7%, 674 companies
62nd percentile in USAmedian 3.5%, 2,594 companies
The Cooper Companies, Inc.16.7%FY2025
84th percentile in Healthcaremedian -7.7%, 674 companies
81st percentile in USAmedian 3.5%, 2,594 companies
West Pharmaceutical Services, Inc.19.0%FY2025
87th percentile in Healthcaremedian -7.7%, 674 companies
84th percentile in USAmedian 3.5%, 2,594 companies
ResMed Inc.33.4%FY2026
96th percentile in Healthcaremedian -7.7%, 674 companies
95th percentile in USAmedian 3.5%, 2,594 companies
Merit Medical Systems, Inc.12.2%FY2025
76th percentile in Healthcaremedian -7.7%, 674 companies
73rd percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$3.5 B$7.0 B$10.5 B$13.9 B2008201020122014201620182020202220242026Hologic, Inc. $4.1 BGlaukos Corporation $507 MBaxter International Inc. $11.2 BRepligen Corporation $738 MThe Cooper Companies, Inc. $4.1 BWest Pharmaceutical Services, Inc. $3.1 BResMed Inc. $5.7 BMerit Medical Systems, Inc. $1.5 B

Rank in the group

1st2nd3rd4th5th6th7th8th20122013201420152016201720182019202020212022202320242025Hologic, Inc.: 2nd of 7 in 2012Hologic, Inc.: 2nd of 8 in 2013Hologic, Inc.: 2nd of 8 in 2014Hologic, Inc.: 2nd of 8 in 2015Hologic, Inc.: 2nd of 8 in 2016Hologic, Inc.: 2nd of 8 in 2017Hologic, Inc.: 2nd of 8 in 2018Hologic, Inc.: 2nd of 8 in 2019Hologic, Inc.: 2nd of 8 in 2020Hologic, Inc.: 2nd of 8 in 2021Hologic, Inc.: 2nd of 8 in 2022Hologic, Inc.: 3rd of 8 in 2023Hologic, Inc.: 3rd of 8 in 2024Hologic, Inc.: 3rd of 8 in 2025Hologic, Inc.Glaukos Corporation: 8th of 8 in 2013Glaukos Corporation: 8th of 8 in 2014Glaukos Corporation: 8th of 8 in 2015Glaukos Corporation: 7th of 8 in 2016Glaukos Corporation: 7th of 8 in 2017Glaukos Corporation: 8th of 8 in 2018Glaukos Corporation: 8th of 8 in 2019Glaukos Corporation: 8th of 8 in 2020Glaukos Corporation: 8th of 8 in 2021Glaukos Corporation: 8th of 8 in 2022Glaukos Corporation: 8th of 8 in 2023Glaukos Corporation: 8th of 8 in 2024Glaukos Corporation: 8th of 8 in 2025Glaukos CorporationBaxter International Inc.: 1st of 7 in 2012Baxter International Inc.: 1st of 8 in 2013Baxter International Inc.: 1st of 8 in 2014Baxter International Inc.: 1st of 8 in 2015Baxter International Inc.: 1st of 8 in 2016Baxter International Inc.: 1st of 8 in 2017Baxter International Inc.: 1st of 8 in 2018Baxter International Inc.: 1st of 8 in 2019Baxter International Inc.: 1st of 8 in 2020Baxter International Inc.: 1st of 8 in 2021Baxter International Inc.: 1st of 8 in 2022Baxter International Inc.: 1st of 8 in 2023Baxter International Inc.: 1st of 8 in 2024Baxter International Inc.: 1st of 8 in 2025Baxter International Inc.Repligen Corporation: 7th of 7 in 2012Repligen Corporation: 7th of 8 in 2013Repligen Corporation: 7th of 8 in 2014Repligen Corporation: 7th of 8 in 2015Repligen Corporation: 8th of 8 in 2016Repligen Corporation: 8th of 8 in 2017Repligen Corporation: 7th of 8 in 2018Repligen Corporation: 7th of 8 in 2019Repligen Corporation: 7th of 8 in 2020Repligen Corporation: 7th of 8 in 2021Repligen Corporation: 7th of 8 in 2022Repligen Corporation: 7th of 8 in 2023Repligen Corporation: 7th of 8 in 2024Repligen Corporation: 7th of 8 in 2025Repligen CorporationThe Cooper Companies, Inc.: 3rd of 7 in 2012The Cooper Companies, Inc.: 3rd of 8 in 2013The Cooper Companies, Inc.: 3rd of 8 in 2014The Cooper Companies, Inc.: 3rd of 8 in 2015The Cooper Companies, Inc.: 3rd of 8 in 2016The Cooper Companies, Inc.: 3rd of 8 in 2017The Cooper Companies, Inc.: 3rd of 8 in 2018The Cooper Companies, Inc.: 3rd of 8 in 2019The Cooper Companies, Inc.: 4th of 8 in 2020The Cooper Companies, Inc.: 4th of 8 in 2021The Cooper Companies, Inc.: 4th of 8 in 2022The Cooper Companies, Inc.: 4th of 8 in 2023The Cooper Companies, Inc.: 4th of 8 in 2024The Cooper Companies, Inc.: 4th of 8 in 2025The Cooper Companies, Inc.West Pharmaceutical Services, Inc.: 5th of 7 in 2012West Pharmaceutical Services, Inc.: 5th of 8 in 2013West Pharmaceutical Services, Inc.: 5th of 8 in 2014West Pharmaceutical Services, Inc.: 5th of 8 in 2015West Pharmaceutical Services, Inc.: 5th of 8 in 2016West Pharmaceutical Services, Inc.: 5th of 8 in 2017West Pharmaceutical Services, Inc.: 5th of 8 in 2018West Pharmaceutical Services, Inc.: 5th of 8 in 2019West Pharmaceutical Services, Inc.: 5th of 8 in 2020West Pharmaceutical Services, Inc.: 5th of 8 in 2021West Pharmaceutical Services, Inc.: 5th of 8 in 2022West Pharmaceutical Services, Inc.: 5th of 8 in 2023West Pharmaceutical Services, Inc.: 5th of 8 in 2024West Pharmaceutical Services, Inc.: 5th of 8 in 2025West Pharmaceutical ServicResMed Inc.: 4th of 7 in 2012ResMed Inc.: 4th of 8 in 2013ResMed Inc.: 4th of 8 in 2014ResMed Inc.: 4th of 8 in 2015ResMed Inc.: 4th of 8 in 2016ResMed Inc.: 4th of 8 in 2017ResMed Inc.: 4th of 8 in 2018ResMed Inc.: 4th of 8 in 2019ResMed Inc.: 3rd of 8 in 2020ResMed Inc.: 3rd of 8 in 2021ResMed Inc.: 3rd of 8 in 2022ResMed Inc.: 2nd of 8 in 2023ResMed Inc.: 2nd of 8 in 2024ResMed Inc.: 2nd of 8 in 2025ResMed Inc.Merit Medical Systems, Inc.: 6th of 7 in 2012Merit Medical Systems, Inc.: 6th of 8 in 2013Merit Medical Systems, Inc.: 6th of 8 in 2014Merit Medical Systems, Inc.: 6th of 8 in 2015Merit Medical Systems, Inc.: 6th of 8 in 2016Merit Medical Systems, Inc.: 6th of 8 in 2017Merit Medical Systems, Inc.: 6th of 8 in 2018Merit Medical Systems, Inc.: 6th of 8 in 2019Merit Medical Systems, Inc.: 6th of 8 in 2020Merit Medical Systems, Inc.: 6th of 8 in 2021Merit Medical Systems, Inc.: 6th of 8 in 2022Merit Medical Systems, Inc.: 6th of 8 in 2023Merit Medical Systems, Inc.: 6th of 8 in 2024Merit Medical Systems, Inc.: 6th of 8 in 2025Merit Medical Systems, Inc
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearHologic, Inc.Glaukos CorporationBaxter International Inc.Repligen CorporationThe Cooper Companies, Inc.West Pharmaceutical Services, Inc.ResMed Inc.Merit Medical Systems, Inc.
2026——————$5.7 BSEC—
2025$4.1 BSEC3rd$507 MSEC8th$11.2 BSEC1st$738 MSEC7th$4.1 BSEC4th$3.1 BSEC5th$5.1 BSEC2nd$1.5 BSEC6th
2024$4.0 BSEC3rd$383 MSEC8th$10.6 BSEC1st$634 MSEC7th$3.9 BSEC4th$2.9 BSEC5th$4.7 BSEC2nd$1.4 BSEC6th
2023$4.0 BSEC3rd$315 MSEC8th$10.4 BSEC1st$632 MSEC7th$3.6 BSEC4th$2.9 BSEC5th$4.2 BSEC2nd$1.3 BSEC6th
2022$4.9 BSEC2nd$283 MSEC8th$10.1 BSEC1st$802 MSEC7th$3.3 BSEC4th$2.9 BSEC5th$3.6 BSEC3rd$1.2 BSEC6th
2021$5.6 BSEC2nd$294 MSEC8th$12.1 BSEC1st$671 MSEC7th$2.9 BSEC4th$2.8 BSEC5th$3.2 BSEC3rd$1.1 BSEC6th
2020$3.8 BSEC2nd$225 MSEC8th$11.7 BSEC1st$366 MSEC7th$2.4 BSEC4th$2.1 BSEC5th$3.0 BSEC3rd$964 MSEC6th
2019$3.4 BSEC2nd$237 MSEC8th$11.4 BSEC1st$270 MSEC7th$2.7 BSEC3rd$1.8 BSEC5th$2.6 BSEC4th$995 MSEC6th
2018$3.2 BSEC2nd$181 MSEC8th$11.1 BSEC1st$194 MSEC7th$2.5 BSEC3rd$1.7 BSEC5th$2.3 BSEC4th$883 MSEC6th
2017$3.1 BSEC2nd$159 MSEC7th$10.6 BSEC1st$141 MSEC8th$2.1 BSEC3rd$1.6 BSEC5th$2.1 BSEC4th$728 MSEC6th
2016$2.8 BSEC2nd$114 MSEC7th$10.2 BSEC1st$105 MSEC8th$2.0 BSEC3rd$1.5 BSEC5th$1.8 BSEC4th$604 MSEC6th
2015$2.7 BSEC2nd$72 MSEC8th$10.0 BSEC1st$84 MSEC7th$1.8 BSEC3rd$1.4 BSEC5th$1.7 BSEC4th$542 MSEC6th

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Hologic, Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Glaukos CorporationGKOS · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $14.4 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $14.4 B (Oct 30, 2026) · revenue $507 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Baxter International Inc.BAX · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $12.9 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $12.9 B (Oct 28, 2026) · revenue $11.2 B (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Repligen CorporationRGEN · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $11.5 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $11.5 B (Oct 27, 2026) · revenue $738 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • The Cooper Companies, Inc.COO · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $11.3 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $11.3 B (Oct 29, 2026) · revenue $4.1 B (year to October 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • West Pharmaceutical Services, Inc.WST · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $27.1 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $27.1 B (Oct 21, 2026) · revenue $3.1 B (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • ResMed Inc.RMD · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $35.3 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $35.3 B (Oct 28, 2026) · revenue $5.7 B (year to June 2026)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    In the group
  • Merit Medical Systems, Inc.MMSI · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $5.6 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $5.6 B (Oct 26, 2026) · revenue $1.5 B (year to December 2025)
    93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)
    In the group
  • Teleflex IncorporatedTFX · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $5.5 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $5.5 B (Oct 28, 2026) · revenue $2.0 B (year to December 2025)
    93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)
    + Add
  • Haemonetics CorporationHAE · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $5.5 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $5.5 B (Oct 28, 2026) · revenue $1.3 B (year to March 2026)
    93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)
    + Add
  • Becton, Dickinson and CompanyBDX · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $54.0 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $54.0 B (Oct 30, 2026) · revenue $21.8 B (year to September 2025)
    92 of 100 (industry or sector 50 + size 22 + country 15 + figures on file 5)
    + Add
  • Masimo CorporationMASI · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $9.4 B market cap against $16.9 B · Same country: USA
    Market cap $9.4 B (last known, Aug 1, 2026) · revenue $1.5 B (year to January 2026)
    91 of 100 (industry or sector 50 + size 26 + country 15)
    + Add
  • iRhythm Technologies, Inc.IRTC · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $4.3 B market cap against $16.9 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $4.3 B (Oct 30, 2026) · revenue $747 M (year to December 2025)
    91 of 100 (industry or sector 50 + size 21 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.